ArticleAutoimmune diseases2011
Three types of striational antibodies in myasthenia gravis.
Article in Autoimmune diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 97 citations in OpenAlex.
- On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales.Journal of neuromuscular diseases · 2026Review
- Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.Orphanet journal of rare diseases · 2025Article
- Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies.Frontiers in neurology · 2025Article
- Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations.Frontiers in neurology · 2025Article
- A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.Internal medicine (Tokyo, Japan) · 2024Article
- Cardiac implications in myasthenia gravis.World journal of clinical cases · 2024Article
- Protein networking: nicotinic acetylcholine receptors and their protein-protein-associations.Molecular and cellular biochemistry · 2024Review
- Perioperative cardiac risks in myasthenia gravis.World journal of clinical cases · 2024Article
- Article
- Peripheral nervous system adverse events associated with immune checkpoint inhibitors.Journal of neurology · 2023Article
- Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies.Frontiers in immunology · 2023Article
- Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.Internal medicine (Tokyo, Japan) · 2023Article
- Myocardial Injury in Hospitalized Patients with Myasthenia Gravis.Journal of clinical medicine · 2022Article
- Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.Internal medicine (Tokyo, Japan) · 2022Article
- Anti-MuSK Positive Myasthenia Gravis with Anti-Lrp4 and Anti-titin Antibodies.Internal medicine (Tokyo, Japan) · 2021Article
- Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2020Review
- Fulminant myocarditis with myositis of ocular and respiratory muscles.Nagoya journal of medical science · 2020Article
- Article
- Neuroimmunogastroenterology: At the Interface of Neuroimmunology and Gastroenterology.Frontiers in neurology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4 autoantibodies has become available, involving 12-15% of all MG patients. The presence of striational antibodies is associated with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more specific and useful clinical information in MG patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.